Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
diphtheria + tetanus + acellular pertussis-Zhejiang Provincial Center for Disease Control and Prevention-diphtheria-tetanus-pertussis
- Development stage
- Unknown
- Lead developer
- Zhejiang Provincial Centre for Disease Control and Prevention
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
This co-purified diphtheria, tetanus, and acellular pertussis (DTaP) combined vaccine is a biologic product used for active immunization against diphtheria, tetanus, and pertussis. It contains diphtheria toxoid, tetanus toxoid, and acellular pertussis antigens, specifically pertussis toxoid (PT) and filamentous hemagglutinin (FHA). The vaccine is manufactured using a co-purification technique and is part of China's National Immunization Program (NIP). A Phase 4 randomized controlled trial (NCT05870631) conducted by the Zhejiang Provincial Center for Disease Control and Prevention evaluated its safety and immunogenicity as a fifth-dose booster in 6-year-old children, demonstrating high seroconversion rates for pertussis antibodies and a favorable safety profile compared to the DT vaccine.
- Other names
- Co-purified DTaPAdsorbed Diphtheria, Tetanus, Acellular Pertussis Combined VaccineDTaP vaccine
02
Targets
Diphtheria toxinFHA (Filamentous hemagglutinin)
Beyond the preview
Go deeper on diphtheria + tetanus + acellular pertussis-Zhejiang Provincial Center for Disease Control and Prevention-diphtheria-tetanus-pertussis.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on diphtheria + tetanus + acellular pertussis-Zhejiang Provincial Center for Disease Control and Prevention-diphtheria-tetanus-pertussis.